Sanofi, a global healthcare leader, announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing authorization for insulin glargine [rDNA origin] injection, 300 U/mL, a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus, where treatment with insulin is needed. Known as Toujeo in the US and Europe, the new insulin treatment will be available in Japan under the trade name Lantus XR.
"For patients requiring basal insulin, Lantus XR could positively impact hypoglycemia during the critical initiation phase, when most titration occurs, and beyond," said Professor Masato Odawara of Tokyo Medical University. "Japan-specific data show that Lantus XR patients experienced less nocturnal hypoglycemia and no increase in hypoglycemia at any time of the day. This outcome was delivered with glycemic control comparable to Lantus and is consistent with the findings in the global EDITION programme in people with type 2 diabetes."
According to the MHLW, there are approximately 9.5 million people living with diabetes in Japan.
"In just four months, Sanofi's next generation basal insulin has been granted marketing authorization by three major regulatory authorities," said Pierre Chancel, senior vice president, head of global diabetes, Sanofi. "This first approval in Asia adds to the momentum of an active launch year, and it highlights our commitment to improving diabetes care worldwide."
The MHLW decision is based on the results of the EDITION Phase III study programme, an extensive series of studies evaluating the efficacy and safety of Toujeo / Lantus XR compared with Lantus in more than 3,500 adults with type 1 or type 2 diabetes who were uncontrolled on their current therapy. The EDITION program established the favourable Toujeo/Lantus XR efficacy and safety profile and included the EDITION JP 1 and JP 2 studies, which involved over 450 Japanese people with type 1 or type 2 diabetes.
Toujeo is now available in the US, Germany, Denmark and the Netherlands and has been registered in Australia. The product will become available in other countries in the coming months.
Despite basal insulin being a cornerstone treatment for diabetes for decades, significant unmet medical needs remain a reality, with approximately half of patients on treatment not reaching their blood sugar level targets. In addition, optimal insulin dose is often not reached during initiation or maintenance phase. Toujeo / Lantus XR is a next-generation, once-daily basal insulin based on a broadly-used molecule (insulin glargine) with a well-established benefit-risk profile. Its compact subcutaneous depot leads to more stable and more prolonged pharmacokinetic/pharmacodynamic (PK/PD) profiles. The approved brand name for insulin glargine (rDNA origin) injection 300 U/mL in countries other than Japan is Toujeo; its brand name in Japan is Lantus XR. Toujeo has been approved by the US Food and Drug Administration (FDA), the European Commission and Health Canada, and is under review by other regulatory authorities around the world.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.